The role of genetics for biomarker development in neurodegeneration

Bertram, L.; Hampel, H.

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

The role of genetics for biomarker development in neurodegeneration

MPG-Autoren

/persons/resource/persons50098

Bertram, L.
Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

Externe Ressourcen

Es sind keine externen Ressourcen hinterlegt

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Bertram, L., & Hampel, H. (2011). The role of genetics for biomarker development in neurodegeneration. Progress in Neurobiology, 95(4), 501-4. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22005514 http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271063&_user=28761&_pii=S030100821100178X&_check=y&_origin=article&_zone=toolbar&_coverDate=31-Dec-2011&view=c&originContentFamily=serial&wchp=dGLbVlt-zSkzV&md5=669cdcb634187e64aaf4a4b67f7b7540/1-s2.0-S030100821100178X-main.pdf http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271063&_user=28761&_pii=S030100821100178X&_check=y&_origin=article&_zone=toolbar&_coverDate=31-Dec-2011&view=c&originContentFamily=serial&wchp=dGLbVlk-zSkzS&md5=669cdcb634187e64aaf4a4b67f7b7540/1-s2.0-S030100821100178X-main.pdf.

Zitierlink: https://hdl.handle.net/11858/00-001M-0000-0010-7900-6

Zusammenfassung

Research on biomarkers and genetics shares a number of objectives, including the identification of novel disease mechanisms, optimization of therapeutic studies, and improvement of diagnosis and prognosis. The latter is of particular relevance in neurodegenerative diseases where the underlying molecular processes often go on for decades until the first clinical symptoms appear. In this commentary we review the potential contribution that insight gained from genetic research may have on biomarker development in neurodegeneration. We argue that future progress will largely depend on a widespread application of novel high-throughput technologies now becoming available in both fields.